Trials / Unknown
UnknownNCT02801591
Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET
Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of Poor Ovarian Response (POR) Clinical Outcome in Patients Undergoing in Vitro Fertilization / Embryo Transfer (IVF/ET)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 240 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- Female
- Age
- 30 Years – 42 Years
- Healthy volunteers
- Not accepted
Summary
Observe the clinical efficacy and safety of Recombinant Human Growth Hormone Injection assisted in the treatment of the patients with poor ovarian response in vitro fertilization and embryo transfer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Conventional ovarian stimulation proctol without rhGH |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2017-02-01
- First posted
- 2016-06-16
- Last updated
- 2016-06-16
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02801591. Inclusion in this directory is not an endorsement.